Antigenic specificity of chlorpromazine-induced antinuclear antibodies.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis*; D000918:Antibody Specificity; D000927:Anticonvulsants / Q000627:therapeutic use; D000937:Antigen-Antibody Reactions; D002746:Chlorpromazine / Q000627:therapeutic use*; D003168:Complement Fixation Tests; D004277:DNA, Single-Stranded; D000939:Epitopes; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009698:Nucleoproteins; D011618:Psychotic Disorders / Q000188:drug therapy; D012737:Sex Factors; D013997:Time Factors
D000974:Antibodies, Antinuclear; D000927:Anticonvulsants; D004277:DNA, Single-Stranded; D000939:Epitopes; D009698:Nucleoproteins; D002746:Chlorpromazine; D007538:Isoniazid